Back to results
US 2025/0019452 A1Published application
Humanized anti-il-1r3 antibody and methods of use
AssigneeSanofi Biotechnology
InventorsChristian LANGE, Ziyu LI, Björn STEINMANN, Hanno SJUTS, Sandra WEIL
Life of this patent
Estimating the term…
Abstract
An antibody that specifically binds to IL-1R3, comprising an antibody heavy chain amino acid sequence of SEQ ID NO: 1 and a light chain amino acid sequence of SEQ ID NO: 2. A pharmaceutical composition is provided comprising the said antibody and a pharmaceutically acceptable diluent, carrier or excipient. Also said antibody for use in treating a disease or disorder in a subject in need thereof. The disease or disorder may be an autoimmune or autoinflammatory disease or disorder.
Claims11
-15. (canceled)
An antibody that specifically binds to IL-1R3, wherein the antibody is selected from the group consisting of:
- (a) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 24, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 29, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (b) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 25, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 30, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (c) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 25, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 31, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (d) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 25, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 32, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (e) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 26, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 30, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (f) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 26, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 31, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (g) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 26, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 32, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (h) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 27, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 30, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (i) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 27, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 31, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (j) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 27, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 32, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (k) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 28, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 30, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (l) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 28, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 31, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (m) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 28, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 32, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (o) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 33, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 34, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (p) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 35, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 36, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (q) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 37, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 44, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (r) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 38, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 45, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (s) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 39, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 46, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (t) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 40, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 47, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (u) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 41, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 48, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- (v) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 42, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 49, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering;
- and
- (w) an antibody comprising an antibody heavy chain variable (VH) domain amino acid sequence of SEQ ID NO:
- 43, an antibody light chain variable (VL) domain amino acid sequence of SEQ ID NO:
- 50, and an IgG4 Fc domain, wherein the IgG4 Fc domain comprises an F234A substitution, an L235A substitution, and an S228P substitution, according to EU numbering.
64 more elements
Dependencies are inferred from the claim text.